Introduction: Lifecycle management strategies for dexamethasone injectables are essential for pharmaceutical manufacturers aiming to sustain product relevance, regulatory compliance, and […]
Lifecycle Management Strategies for Dexamethasone Injectables Read More »
Introduction: Method validation for extractables and leachables testing is a regulatory non-negotiable — without a fully documented, ICH Q2(R2)-compliant validation
Method Validation for Extractables and Leachables Testing: What ICH Q2(R2) Requires Read More »
Multi-Attribute Monitoring (MAM) for Therapeutic Peptide Characterization: A Modern LC-MS Workflow Introduction Liquid chromatography-mass spectrometry (LC-MS)-based Multi-Attribute Monitoring (MAM) has
Introduction: A receptor-targeted peptide oligonucleotide conjugate (POC) is an engineered biotherapeutic that links an antisense oligonucleotide (ASO) payload to a
Introduction to Regulatory Expectations for Peptide-Oligonucleotide Conjugates in IND Submissions The regulatory pathway for advancing Peptide-Oligonucleotide Conjugates (POCs) in Investigational
Regulatory Expectations for Peptide-Oligonucleotide Conjugates in IND Submissions Read More »
Introduction: Why Immunogenicity Assessment in Biosimilar Development Is Non-Negotiable Immunogenicity assessment in biosimilar development refers to the structured process of
Introduction How Does a Comprehensive E&L Program Mitigate Risk in Prefilled Syringe Development? A comprehensive Extractables & Leachables (E&L) program
Extractables & Leachables (E&L) Testing Services for Prefilled Syringe Drug Products Read More »
Introduction to Biosimilar Cell Line Engineering In the biopharmaceutical industry, Cell Line Development for Biosimilars is a highly regulated, comparability-driven
Introduction The successful clinical development and regulatory approval of hybrid biotherapeutics depend on advanced analytical strategies for the Structural Characterization
Introduction: The landscape of incretin-based therapies has expanded far beyond the first-generation GLP-1 receptor agonists. Regulatory submissions for GLP-2 and
